ANGIODYNAMICS, INC.

In 2024, Cynosure and Hahn & Company merged with Lutronic, enhancing their global presence. Summus Medical Laser partnered with Regenmed for a real-world evidence program. Alma Lasers expanded globally. The medical laser industry is evolving with technologies like Pico, Nanosecond, and Fractional Lasers, and LLLT for various treatments. Despite high costs, the market grows, especially in North America, driven by cosmetic and minimally invasive procedures.

Baxter International launched five new injectable pharmaceutical products in the U.S., totaling 10 product launches in 2024, reinforcing its leadership in high-value, specialty injectables and strengthening its Pharmaceutical business segment.

AngioDynamics received FDA 510(k) clearance for its NanoKnife system in prostate tissue ablation for intermediate-risk prostate cancer patients, following the PRESERVE clinical study. The study showed 84% of patients free from significant in-field disease at 12 months, with favorable quality-of-life outcomes. The NanoKnife system uses non-thermal, radiation-free irreversible electroporation to ablate prostate tissue precisely, aiming to preserve urinary and sexual function.

AngioDynamics' NanoKnife system gains FDA clearance for prostate cancer treatment, using irreversible electroporation to destroy cancer cells with electrical pulses, offering safety advantages over thermal ablation. The FDA based its decision on the PRESERVE study, which showed 84% of men were disease-free at one year post-procedure, with improved quality of life outcomes.

The FDA granted 510(k) clearance to the NanoKnife System for prostate tissue ablation, based on the PRESERVE trial's results showing 84% negative in-field biopsy rate at 12 months and 95.4% urinary continence preservation.

AngioDynamics receives FDA clearance for NanoKnife System for prostate tissue ablation, following successful completion of the PRESERVE clinical study. The system offers a minimally invasive, non-thermal, radiation-free treatment for intermediate-risk prostate cancer, preserving urinary continence and erectile function.

R3 Vascular received FDA IDE approval for its ELITE-BTK trial of Magnitude, a bioresorbable scaffold for treating chronic limb-threatening ischemia due to below-the-knee PAD. The trial, set to begin in Q1 2025, follows $87m in series B funding and will involve up to 60 global sites. PAD affects 8-12 million people in the US, with 18.4 million diagnosed cases globally in 2023.

AngioDynamics partners with UCLH to launch a registry study evaluating the long-term effects of NanoKnife for treating unifocal intermediate-risk prostate cancer, aiming to validate its safety and efficacy, reduce the need for radical interventions, and preserve patients' quality of life.